| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7268156 | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Jun, 2023
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40000 | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Jun, 2015
(8 years ago) | |
| US6022562 | WOODWARD | Medicinal and/or nutritional microcapsules for oral administration |
Oct, 2015
(8 years ago) | |
|
USRE40000 (Pediatric) | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Dec, 2015
(8 years ago) | |
|
US6022562 (Pediatric) | WOODWARD | Medicinal and/or nutritional microcapsules for oral administration |
Apr, 2016
(8 years ago) | |
|
US7268156 (Pediatric) | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Dec, 2023
(3 months ago) | |
| US8101209 | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Sep, 2025
(1 year, 4 months from now) | |
|
US8101209 (Pediatric) | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Mar, 2026
(1 year, 10 months from now) | |
Coreg Cr is owned by Woodward.
Coreg Cr contains Carvedilol Phosphate.
Coreg Cr has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Coreg Cr are:
- USRE40000
- US6022562
- USRE40000*PED
- US6022562*PED
- US7268156*PED
- US7268156
Coreg Cr was authorised for market use on 20 October, 2006.
Coreg Cr is available in capsule, extended release;oral dosage forms.
Coreg Cr can be used as decreasing mortality caused by congestive heart failure, treatment of hypertension.
The generics of Coreg Cr are possible to be released after 11 March, 2026.
Drugs and Companies using CARVEDILOL PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: Decreasing mortality caused by congestive heart failure; Treatment of hypertension
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
COREG CR family patents
